At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Pirtobrutinib (drug)
- How long the study runs
- Study runs about 91 months (dates as stated)
- About the drug or intervention
- Pirtobrutinib — drug: Administered orally.
- Patient visit burden
- Not specified by the sponsor
In plain English
This study looks at a medicine called pirtobrutinib (also known by the code LY3527727) in people who have already been treated for chronic lymphocytic leukaemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma. These are types of blood cancer. The study is run by Eli Lilly and Company.
Who can take part
- You are already taking part in and still active in the original study, called LOXO-BTK-18001. Being active means you are either receiving the study medicine, or you are in the short-term follow-up period, or in the long-term follow-up period.
Who may not be able to
- You were in the Phase 1b group of the original study, LOXO-BTK-18001.
What taking part involves
- • Not stated — ask the trial team.
Time commitment: Not stated — ask the trial team about how many visits there are, how long the study lasts, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 279
- Started
- 2025-05-20
- Last checked
- 2026-02
Plain English Summary
What is this study?
- • Testing a new treatment for chronic lymphocytic leukemia
- • Phase4 - 279 participants
- • Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with chronic lymphocytic leukemia
Where?
- • Leeds - St James's University Hospital
- • Oxford - Churchill Hospital
- • Plymouth - Derriford Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the...
- ✓receiving study intervention
- ✓in the short-term follow-up period, or
- ✓in the long-term follow-up period
Who cannot take part
- ✗Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001
See the full criteria
Where Is This Study? (3 UK sites)
St James's University Hospital
Leeds LS9 7TF, United Kingdom
Churchill Hospital
Oxford OX3 7LE, United Kingdom
Derriford Hospital
Plymouth PL6 8DH, United Kingdom
How to Get in Touch
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Sponsor contactCONTACT
Physicians interested in becoming principal investigators please contact
Sponsor contactCONTACT